LEAP THERAPEUTICS INC (LPTX) Fundamental Analysis & Valuation

NASDAQ:LPTX • US52187K2006

Current stock price

2.05 USD
+1.61 (+368.57%)
At close:
1.55 USD
-0.5 (-24.39%)
After Hours:

This LPTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LPTX Profitability Analysis

1.1 Basic Checks

  • LPTX had negative earnings in the past year.
  • LPTX had a negative operating cash flow in the past year.
  • LPTX had negative earnings in each of the past 5 years.
  • LPTX had a negative operating cash flow in each of the past 5 years.
LPTX Yearly Net Income VS EBIT VS OCF VS FCFLPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -327.74%, LPTX is doing worse than 94.21% of the companies in the same industry.
  • LPTX has a Return On Equity of -1148.94%. This is amonst the worse of the industry: LPTX underperforms 81.12% of its industry peers.
Industry RankSector Rank
ROA -327.74%
ROE -1148.94%
ROIC N/A
ROA(3y)-109.13%
ROA(5y)-86.19%
ROE(3y)-140.51%
ROE(5y)-107.95%
ROIC(3y)N/A
ROIC(5y)N/A
LPTX Yearly ROA, ROE, ROICLPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LPTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPTX Yearly Profit, Operating, Gross MarginsLPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. LPTX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, LPTX has more shares outstanding
  • LPTX has more shares outstanding than it did 5 years ago.
  • LPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LPTX Yearly Shares OutstandingLPTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
LPTX Yearly Total Debt VS Total AssetsLPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • LPTX has an Altman-Z score of -39.98. This is a bad value and indicates that LPTX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -39.98, LPTX is doing worse than 91.78% of the companies in the same industry.
  • LPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -39.98
ROIC/WACCN/A
WACCN/A
LPTX Yearly LT Debt VS Equity VS FCFLPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • LPTX has a Current Ratio of 1.34. This is a normal value and indicates that LPTX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.34, LPTX is not doing good in the industry: 82.99% of the companies in the same industry are doing better.
  • LPTX has a Quick Ratio of 1.34. This is a normal value and indicates that LPTX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of LPTX (1.34) is worse than 82.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.34
Quick Ratio 1.34
LPTX Yearly Current Assets VS Current LiabilitesLPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LPTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.79% over the past year.
EPS 1Y (TTM)36.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, LPTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.37% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.47%
EPS Next 2Y30.62%
EPS Next 3Y19.23%
EPS Next 5Y13.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LPTX Yearly Revenue VS EstimatesLPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2029 2030 2031 2032 50M 100M 150M
LPTX Yearly EPS VS EstimatesLPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. LPTX Valuation Analysis

4.1 Price/Earnings Ratio

  • LPTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LPTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LPTX Price Earnings VS Forward Price EarningsLPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPTX Per share dataLPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LPTX's earnings are expected to grow with 19.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.62%
EPS Next 3Y19.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LPTX Dividend Analysis

5.1 Amount

  • LPTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LPTX Fundamentals: All Metrics, Ratios and Statistics

LEAP THERAPEUTICS INC

NASDAQ:LPTX (11/12/2025, 8:00:00 PM)

After market: 1.55 -0.5 (-24.39%)

2.05

+1.61 (+368.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-24
Inst Owners22.06%
Inst Owner Change-45.24%
Ins Owners0.46%
Ins Owner Change0%
Market Cap116.13M
Revenue(TTM)N/A
Net Income(TTM)-65.69M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.34%
Min EPS beat(2)-35.23%
Max EPS beat(2)4.54%
EPS beat(4)2
Avg EPS beat(4)-5.33%
Min EPS beat(4)-35.23%
Max EPS beat(4)10.13%
EPS beat(8)5
Avg EPS beat(8)0.77%
EPS beat(12)7
Avg EPS beat(12)-17.41%
EPS beat(16)9
Avg EPS beat(16)-16.37%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 20.31
P/tB 20.31
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-1.06
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -327.74%
ROE -1148.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-109.13%
ROA(5y)-86.19%
ROE(3y)-140.51%
ROE(5y)-107.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.34
Quick Ratio 1.34
Altman-Z -39.98
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.82%
EPS Next Y38.47%
EPS Next 2Y30.62%
EPS Next 3Y19.23%
EPS Next 5Y13.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.77%
OCF growth 3YN/A
OCF growth 5YN/A

LEAP THERAPEUTICS INC / LPTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for LEAP THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to LPTX.


Can you provide the valuation status for LEAP THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to LEAP THERAPEUTICS INC (LPTX). This can be considered as Overvalued.


What is the profitability of LPTX stock?

LEAP THERAPEUTICS INC (LPTX) has a profitability rating of 0 / 10.